Chinese instructions for Amivantamab

1. Indications:

Amivantamab (Amivantamab) is mainly used to treat some specific subtypes of non-small cell lung cancer (NSCLC), including EGFR (epidermal Growth factor receptor) gene mutation and MET (muscle-specific casein kinase) gene exon 14 deletion (METex14).

2. Mechanism of action:

Evantumumab is a bispecific antibody that binds to both EGFR and MET molecules. Through this mechanism, evantumumab blocks the abnormal activation of the EGFR and MET signaling pathways, thereby inhibiting the growth and spread of tumor cells.

3. Pharmacology:

1.EGFR:EGFR is a receptor casein kinase involved in regulating cell proliferation and growth. Evantumumab binds to EGFR, inhibits its activity and reduces the growth of tumor cells.

2.MET: MET is another important molecule that is involved in the regulation of cell growth and migration. METex14 deletion is a molecular abnormality in lung cancer. Evantumumab inhibits the activation of this abnormal signaling pathway by binding to MET.

4. Dosage and usage:

Evantumumab is usually given to patients as an intravenous injection (IV). Dosage will be determined by the doctor based on the patient's weight and condition. The treatment period and frequency are also determined based on the patient's specific condition.

5. Side effects:

Common side effects of evantumumab include fatigue, rash, nausea, vomiting, headache, etc. Serious adverse reactions may include difficulty breathing, allergic reactions, etc. Patients should closely monitor adverse reactions during treatment and report them to their doctors in a timely manner.

6. Warnings and precautions:

1.Evantumumab may cause serious adverse reactions and must be used under professional medical supervision.

2.Patients and doctors should work closely together to conduct regular follow-up and monitoring to ensure treatment effectiveness and manage adverse reactions.

3.Evantumumab may cause risks to pregnant women and fetuses, and patients should avoid becoming pregnant or take appropriate contraceptive measures during treatment.

7. Contraindications:

Evantumumab may not be suitable for use in certain circumstances, such as in patients who are allergic to components of the drug or who have serious uncontrollable adverse reactions. Your doctor will decide on a case-by-case basis whether this medication is appropriate.

8. Drug interactions:

While taking evantumumab, patients should inform their doctors about other medications they are taking, including prescription drugs, over-the-counter drugs, and supplements, to avoid potential drug interactions.

9. Medication for special groups:

For elderly patients, patients with impaired liver and kidney function, and other special groups, the dosage and usage of evantumumab may need to be adjusted according to the specific situation. Therefore, doctors will develop an individualized treatment plan based on the needs of the patient.

10. Listing and price situation:

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.

Please note that the specific usage and dosage of evantumumab should be formulated according to the guidance of a doctor, and patients and doctors should actively cooperate to ensure the best therapeutic effect and minimal adverse reactions. In addition, medication inserts may vary slightly from country to country, so the advice of your local health department and medical professional should be followed.